Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Outcomes after recurrence on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with high-risk early-stage triple-negative breast cancer (eTNBC).

Chiara Corti, Qingchun Jin, Catherine Stever et al. Jun 01, 2026 pp. 601-601 10.1200/jco.2026.44.16_suppl.601

601 Background: NCIT improves survival in high-risk eTNBC; however, trial-based data show that most relapses after NCIT ar...

Real-world use of artificial intelligence for automated prognostication and systemic therapeutic decision making in localized RCC.

Kenneth Barker, Muhammad Abdullah Humayun, Hafiz Muhammad Talha Tahir et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16502

e16502 Background: Accurate postoperative risk stratification in localized clear-cell renal cell carcinoma (ccRCC) informs...

Efficacy of tocilizumab in resolving chimeric antigen receptor T-cell (CAR T)–induced cytokine release syndrome (CRS): A pooled clinical trial (CT) analysis of patients (pts) with B-cell lymphoma (BCL).

Soon Jye Kho, Rahul Jain, Sheila Diamond et al. Jun 01, 2026 pp. 7027-7027 10.1200/jco.2026.44.16_suppl.7027

7027 Background: CAR T therapy offers significant efficacy in the treatment of relapsed/refractory hematologic malignancie...

CD4 T-cell reconstitution and CD4:CD8 inversion following lymphodepleting chemotherapy for tumor-infiltrating lymphocyte therapy in metastatic melanoma.

Arkadiusz Z. Dudek, Mohamed A. Aboelatta, Jabra Zarka et al. Jun 01, 2026 pp. 9551-9551 10.1200/jco.2026.44.16_suppl.9551

9551 Background: Lymphodepleting (LD) chemotherapy is required prior to tumor-infiltrating lymphocyte (TIL) therapy, yet t...

Transportation insecurity and RBC transfusion burden in multiple myeloma and related plasma cell disorders in New Mexico: A CRIIS statewide analysis (2013-2019).

Altamash Jawadi, Stephanie Rosenberg, Kevin Angel Silva Parra et al. Jun 01, 2026 pp. 1532-1532 10.1200/jco.2026.44.16_suppl.1532

1532 Background: Multiple myeloma (MM) and related plasma cell disorders are commonly complicated by anemia requiring red...

First-in-human clinical evaluation of ST-01156, an optimized and selective degrader of RNA-binding motif 39 (RBM39): A phase 1 study in advanced solid malignancies with a focus on RBM39-dependent cancers.

Eric Keith Rowinsky, Gregory Michael Cote, George D. Demetri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3164

TPS3164 Background: ST-01156 is an orally administered agent developed to degrade RBM39, a protein target that is principa...

Failure-to-rescue after acute cardiac events in cancer versus non-cancer hospitalizations.

Sharnvir Chattha, Christopher Aboujaoude, Boone Singtong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23241

e23241 Background: Acute cardiac complications are major drivers of inpatient mortality, yet outcomes after theseevents ma...

Development and application research of the intervention program for medication compliance of endocrine therapy in breast cancer patients based on the ICAMO model.

Lei Xu, Yan Hu, Yikai Kong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24099

e24099 Background: Hormone receptor-positive breast cancer is the most common cancer among women globally. Adjuvant endocr...

Frequent monitoring of NSCLC immunotherapy using an mDETECT liquid biopsy to identify therapy response and progression compared to CT scans.

Christopher R. Mueller, Mihaela Mates, Andrew George Robinson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14532

e14532 Background: Response to immunotherapy in metastatic non-small cell lung cancer (NSCLC) is heterogeneous, and early...

Predictive circulating small extracellular vesicle miRNAs for immunochemotherapy response in ES-SCLC.

Wei Zhang, Danni Wang, Yujing Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20146

e20146 Background: Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy with limited treatme...

NGS-based <i>DPYD</i> diplotype analysis beyond conventional targeted variant testing in an ethnically diverse cancer patient cohort.

Satish Sharma, Pritam Kataria, R. K. Choudhary et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15131

e15131 Background: Germline variants in the highly polymorphic DPYD gene are the m...

Long-term responders to sacituzumab govitecan in metastatic triple-negative breast cancer: Real-world outcomes and predictors from a multicenter Italian cohort.

Roberta Caputo, Giuseppe Buono, Claudia Martinelli et al. Jun 01, 2026 pp. 1129-1129 10.1200/jco.2026.44.16_suppl.1129

1129 Background: Sacituzumab govitecan (SG) has reshaped the treatment landscape of metastatic triple-negative breast canc...

Resolving the ambiguity between genomic rearrangements and gene fusions: An AI-augmented structural framework to define therapeutic eligibility in kinase-driven cancers.

Kai Wang, Xi Zhang, Yuda Cao et al. Jun 01, 2026 pp. 1626-1626 10.1200/jco.2026.44.16_suppl.1626

1626 Background: A critical disconnect exists in precision oncology: clinical guidelines frequently conflate genomic "rear...

DEPECA-1 (Defeating Penile Cancer 1): A phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma.

Igor Tsaur, Maria Luisa Barcena, You-Shan Feng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5133

TPS5133 Background: Squamous cell carcinoma of the penis (PeCa) is a rare malignancy with unfavorable outcomes in advanced...

Obesity-associated host factors and intracranial disease phenotype in breast cancer brain metastases.

Catherine Ann Murphy, Italo Fernandes, Farideh Tavangar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14030

e14030 Background: Obesity is characterized by chronic low-grade systemic inflammation and altered metabolic signaling, wh...

Perioperative toripalimab in non-small cell lung cancer: Clinical outcomes and safety from a large prospective real-world study.

Pingping Song, Jian Zeng, Tianqing Chu et al. Jun 01, 2026 pp. 8010-8010 10.1200/jco.2026.44.16_suppl.8010

8010 Background: The phase III NEOTORCH trial demonstrated that perioperative toripalimab significantly improved event-fre...

Cross-continent inter-laboratory transfer of a clinical mass spectrometry lectin magnetic bead assay (LeMBA-MS) for ovarian cancer serum glycoprotein biomarkers.

Fakhrul Syamil Bin Paridul Adras, Cheng Siang Lee, Idris Mohd Najib et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17586

e17586 Background: Accurate non-invasive detection of ovarian cancer can assist in pre-surgical triaging and screening for...

Racial variation in pain medication prescriptions among breast, prostate, and pancreatic cancer patients treated in a large community oncology setting.

Ila Sruti, Zhaohui Su, Robert Lawrence Reid et al. Jun 01, 2026 pp. 1650-1650 10.1200/jco.2026.44.16_suppl.1650

1650 Background: Patients (pts) from racially and ethnically minoritized populations are less likely to receive opioid ana...

Sociodemographic determinants of end-of-life care settings and place of death among patients with lung cancer in the United States.

Ali Mushtaq, Mohanad Baroudi, Darshan Shivanne Gowda et al. Jun 01, 2026 pp. 12077-12077 10.1200/jco.2026.44.16_suppl.12077

12077 Background: Optimizing the place of death is a key component of quality end-of-life (EOL) cancer care, with home and...

A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO₂ combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE.

Samuel A. Goldlust, Michael A. Badruddoja, Nicholas Alfred Blondin et al. Jun 01, 2026 pp. 2065-2065 10.1200/jco.2026.44.16_suppl.2065

2065 Background: Glioblastoma (GBM) contains extensive hypoxic regions due to tumor-associated thrombosis and abnormal vas...

Phase I pharmacokinetic study of high-dose vitamin C dosing regimens in patients with advanced hepatobiliary-pancreatic cancers.

Qing Yin, You Wang, Han Wu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15133

e15133 Background: High-dose vitamin C (HDVC) has demonstrated synergistic or sensitizing effects with chemotherapy and ra...

Keratin 19 (KRT19) as a circulating biomarker to measure disease burden and guide treatment in urothelial cancer.

Eric James Miller, Shu-Hsiang Wang, Marcio A. Diniz et al. Jun 01, 2026 pp. 4591-4591 10.1200/jco.2026.44.16_suppl.4591

4591 Background: Circulating tumor DNA (ctDNA) has emerged as a valuable biomarker in urothelial cancer but remains limite...

Antibody-drug conjugate (ADC) biomarker targets in endometrial cancer (EC): Molecular characterization and implications for therapeutic decision-making.

Britt Kristina Erickson, Michael Toboni, Sharon Wu et al. Jun 01, 2026 pp. 5616-5616 10.1200/jco.2026.44.16_suppl.5616

5616 Background: Given the evolving landscape of ADCs, we evaluated expression of emerging ADC targets in EC and compared...

Impact of adjuvant immunotherapy on stage III acral malignant melanoma (ALM) in a Peruvian cancer center: A real-world experience.

Alexandra Saavedra, Carlos Castañeda, Guillermo Valencia et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21541

e21541 Background: Acral malignant melanoma (AMM) is an aggressive and distinct subtype of melanoma associated with poor p...

Association of the 70-gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.

Steven J. Isakoff, V.K. Gadi, Massimo Cristofanilli et al. Jun 01, 2026 pp. 561-561 10.1200/jco.2026.44.16_suppl.561

561 Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic i...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page